Eli Lilly and Company has entered into a significant research and licensing agreement with SanegeneBio to discover, develop, and commercialize RNA interference (RNAi) therapeutics for metabolic diseases. The deal, announced on November 8, 2025, could be worth up to $1.2 billion for SanegeneBio if all discovery, development, regulatory, and commercial milestones are met. Under the terms of the agreement, Eli Lilly will make an upfront payment and an equity investment in SanegeneBio. Lilly will be responsible for the clinical development and commercialization of the RNAi drug candidates that emerge from the collaboration. SanegeneBio is also eligible to receive tiered royalties on future sales. This partnership allows Lilly to tap into SanegeneBio's drug delivery platform and expand its pipeline with a new class of medicines that work by silencing the messenger RNA molecules that encode for disease-causing proteins.